Multilaboratory Testing in Thrombophilia through the United Kingdom National External Quality Assessment Scheme (Blood Coagulation) Quality Assurance Program

ABSTRACT

We describe here results from the United Kingdom National External Quality Assessment Scheme (UK NEQAS) Thrombophilia Screening Program, in which an average of 21% of 280 centers reported an incorrect diagnosis for a series of plasma samples. Three case studies are described, showing causes of error in individual laboratories, related to the source of reference plasma or reagents. Methodological bias is also described. For protein C (PC) assays 18% of centers reported PC deficiency in a patient homozygous for factor V Leiden. Studies in the NEQAS laboratory confirmed the effect of activated protein C resistance (APCR) on clot-based PC activity assays. Differences in results obtained for PS-deficient subjects with different protein S (PS) activity kits are reported; several subjects would be misdiagnosed as normal with one kit if the manufacturer's reported reference range was adopted instead of a locally determined reference range. Antithrombin (AT) assays were shown to vary in their sensitivity to different molecular defects in the antithrombin gene; 77% of centers employing human thrombin-based activity assays reported a normal AT level in a patient with antithrombin Cambridge II. Sensitivity of the APC resistance test in the absence of factor V-deficient plasma was shown to be improved through normalization of results, and errors in the genetic diagnosis of factor V Leiden and the P20210A prothrombin gene mutation are described. Errors in the diagnosis of thrombophilic defects can therefore be identified through participation in EQA programs, and following dissemination of information, improvements in diagnosis can be demonstrated.

KEYWORDS

Quality assurance testing - antithrombin - protein C - protein S - activated protein C resistance - factor V Leiden - prothrombin gene mutation

REFERENCES

• 1 Faioni E M, Mannucci P M. Diagnostic testing for familial thrombophilia. In: Rowan RM, van Assendelft OW, Preston FE Advanced Laboratory Methods in Haematology London; Arnold 2002
• 2 Egeberg O. On the natural blood coagulation system. Investigations of inhibitor factors based on antithrombin deficient blood.  Thromb Diath Haemorrh. 1965;  14 473-489
• 3 Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia.  Br J Haematol. 2001;  114 512-528
• 4 Tripodi A, Mannucci P M. Laboratory investigation of thrombophilia.  Clin Chem. 2001;  47 1597-1606
• 5 Torrano-Masetti L, Rizzatti E G, Oliveira L CO, Inácio R A, Santos M A, Franco R F. Psychologic impact of thrombophilia screening in asymptomatic relatives of carriers of prothrombotic mutations. J Thromb Haemost 2003 1(suppl 1): (abst OC322)
• 6 Greaves M, Cohen H, Machin S J, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome.  Br J Haematol. 2000;  109 704-715
• 7 Kitchen S, Walker I D, Woods TA L, Preston F E. on behalf of the Steering Committee of the UK NEQAS in Blood Coagulation . Thromboplastin related differences in the determination of International Normalised Ratio: A cause for concern?.  Thromb Haemost. 1994;  72 426-429
• 8 Jennings I, Kitchen S, Cooper P, Makris M, Preston F E. Sensitivity of functional protein S assays to protein S deficiency: a comparative study of three commercial kits.  J Thromb Haemost. 2003;  1 1112-1114
• 9 Preston F E, Kitchen S, Jennings I, Woods T A. A UK National External Quality Assessment scheme (UK NEQAS) for molecular genetic testing for the diagnosis of familial thrombophilia.  Thromb Haemost. 1999;  82 1556-1557
• 10 Cunningham M T, Praestgaard J, Styer P E et al.. A method for proficiency testing of small peer groups in the College of American Pathologists Coagulation Surveys.  Arch Pathol Lab Med. 1999;  123 199-205
• 11 Meijer P, Kluft C, Haverkate F, De Maat M P. The long-term within- and between-laboratory variability for assay of antithrombin, and proteins C and S: results derived from the external quality assessment program for thrombophilia screening of the ECAT Foundation.  J Thromb Haemost. 2003;  1 748-753
• 12 Faioni E M, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci P M. Resistance to activated protein C in nine thrombophilic families: interference in a protein S functional assay.  Thromb Haemost. 1993;  70 1067-1071
• 13 Cooper P C, Hampton K K, Makris M, Abuzenadah A, Paul B, Preston F E. Further evidence that activated protein C resistance can be misdiagnosed as inherited functional protein S deficiency.  Br J Haematol. 1994;  88 201-203
• 14 Ireland H, Bayston T, Thompson E et al.. Apparent heterozygous type II protein C deficiency caused by the factor V 506 Arg to Gln mutation.  Thromb Haemost. 1995;  73 731-732
• 15 Simioni P, de Ronde H, Prandoni P, Saladini M, Bertina R M, Girolami A. Ischemic stroke in young patients with activated protein C resistance: a report of three cases belonging to three different kindreds.  Stroke. 1995;  26 885-890
• 16 Jennings I, Kitchen S, Cooper P C, Rimmer J E, Woods T A, Preston F E. Further evidence that activated protein C resistance affects protein C coagulant activity assays.  Thromb Haemost. 2000;  83 171-172
• 17 De Stefano V, Finazzi G, Mannucci P M. Inherited thrombophilia: pathogenesis, clinical syndromes and management.  Blood. 1996;  87 3531-3544
• 18 Lane D A, Mannucci P M, Bauer K A et al.. Inherited thrombophilia, Part 1.  Thromb Haemost. 1996;  76 651-662
• 19 Faioni E M. Protein S activity. In: Jespersen J, Bertina RM, Haverkate F Laboratory Techniques in Thrombosis: A Manual Amsterdam; Kluwer Academic 1999
• 20 Demers C, Henderson P, Blajchman M A et al.. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.  Thromb Haemost. 1993;  69 231-235
• 21 De Visser M C, Rosendaal F R, Bertina R M. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis.  Blood. 1999;  93 1271-1276
• 22 De Ronde H, Bertina M. Laboratory diagnosis of APC resistance: a critical evaluation of the test and development of diagnostic criteria.  Thromb Haemost. 1994;  72 880-886
• 23 Tripodi A, Chantarangkul V, Negri B, Mannucci P M. Standardisation of the APC resistance test. Effects of normalisation of results by means of pooled normal plasma.  Thromb Haemost. 1998;  79 564-566
• 24 Jennings I, Kitchen S, Woods T A, Preston F E. Normalization does not improve between-laboratory agreement but may improve specificity of some assays for activated protein C resistance.  Blood Coagul Fibrinolysis. 1999;  10 451-453
• 25 Brandt G, Gruppo R, Glueck C J et al.. Sensitivity, specificity and predictive value of modified assays for activated protein C resistance in children.  Thromb Haemost. 1998;  79 567-570
• 26 Lutz C T, Foster P A, Noll W W et al.. Multicenter evaluation of PCR methods for the detection of factor V Leiden (R506Q) genotypes.  Clin Chem. 1998;  44 1356-1358
• 27 Tripodi A, Peyvandi F, Chantarangkul V, Menegatti M, Mannucci P M. Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations-a cause for concern.  Thromb Haemost. 2002;  88 690-691
• 28 Jennings I, Kitchen S, Woods T AL, Preston F E, Greaves M. Clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK NEQAS for Blood Coagulation.  Thromb Haemost. 1997;  77 934-937
• 29 Jennings I, Greaves M, Mackie I J, Kitchen S, Woods T A, Preston F E. UK National External Quality Assessment Scheme for Blood Coagulation. Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines on laboratory methods.  Br J Haematol. 2002;  119 364-369
• 30 Jennings I, Kitchen S, Smith J, Woods T A, Preston F E. Between-centre agreement in homocysteine assays: experience from the UK NEQAS proficiency testing scheme.  Thromb Haemost. 2002;  87 921-922